|
Printable View | E-mail a Link
© Get Permissions
Vaccine Coding Table 2010
Commonly Administered Pediatric Vaccines/Toxoids and Immune Globulins
|
| | Immune Globulin | REMEMBER: Separately report the administration with code 96372 | Manufacturer | Brand | ICD-9-CM |
|---|
| 90378 | Respiratory syncytial virus immune globulin (RSV-IgIM), for intramuscular use, 50 mg, each | MedImmune | Synagis® | V04.82 | | Vaccine | REMEMBER: Separately report the administration with codes 90465-90474* | Manufacturer | Brand | ICD-9-CM | | 90633 | Hepatitis A vaccine, pediatric/adolescent dosage, 2 dose, for intramuscular use | GlaxoSmithKline Merck | HAVRIX® VAQTA® | V05.3 | | 90634 | Hepatitis A vaccine, pediatric/adolescent dosage, 3 dose, for intramuscular use | GlaxoSmithKline | HAVRIX® | V05.3 | | 90644 | Meningococcal conjugate vaccine, serogroups C & Y and Hemophilus influenza B vaccine, tetanus toxoid conjugate (Hib-MenCY-TT), 4-dose schedule, when administered to children 2-15 months of age, for intramuscular use | 
GlaxoSmithKline | 
MenHibrix® | V06.8 | | 90645 | Hemophilus influenza B vaccine (Hib), HbOC conjugate, 4 dose, for intramuscular use | Wyeth | HibTITER® | V03.81 | | 90647 | Hemophilus influenza B vaccine (Hib), PRP-OMP conjugate, 3 dose, for intramuscular use | Merck | PedvaxHIB® | V03.81 | | 90648 | Hemophilus influenza B vaccine (Hib), PRP-T conjugate, 4 dose, for intramuscular use | sanofi pasteur GlaxoSmithKline | ActHIB® HIBERIX® | V03.81 | | 90649 | Human Papilloma virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use | Merck | GARDASIL® | V04.89 | | 90650 | Human Papilloma virus (HPV) vaccine, types 16 and 18, bivalent, 3 dose schedule, for intramuscular use | GlaxoSmithKline | CERVARIX™ | V04.89 | | 90655 | Influenza virus vaccine, split virus, preservative free, for children 6-35 months of age, for intramuscular use | sanofi pasteur | Fluzone No Preservative Pediatric® | V04.81 | | 90656 | Influenza virus vaccine, split virus, preservative free, when administered to 3 years of age and above, for intramuscular use | sanofi pasteur | Fluzone No Preservative® | V04.81 | Novartis | Fluvirin® | GlaxoSmithKline | FLUARIX™ | | 90657 | Influenza virus vaccine, split virus, 635 months dosage, for intramuscular use | sanofi pasteur | Fluzone® | V04.81 | | Novartis | Fluvirin® | | 90658 | Influenza virus vaccine, split virus, 3 years and older dosage, for intramuscular use | sanofi pasteur | Fluzone® | V04.81 | | Novartis | Fluvirin® | | 90660 | Influenza virus vaccine, live, intranasal use | MedImmune | FluMist® | V04.81 | | 90661 | Influenza virus vaccine, derived from cell cultures, subunit, preservative and antibiotic free, for intramuscular use | 
| 
| V04.81 | | 90662 | Influenza virus vaccine, split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use | 
| 
| V04.81 | | 90663 | Influenza virus vaccine, pandemic formulation, H1N1 | ‡ | ‡ | V04.81 | | 90669 | Pneumococcal conjugate vaccine, 7 valent, for intramuscular use | Wyeth | Prevnar® | V03.82 | | 90670 | Pneumococcal conjugate vaccine, 13 valent, for intramuscular use | Wyeth | PREVNAR 13™ | V03.82 | | 90680 | Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use | Merck | RotaTeq® | V04.89 | | 90681 | Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use | GlaxoSmithKline | ROTARIX® | V04.89 | | 90696 | Diphtheria, tetanus toxoids, and acellular pertussis vaccine and poliovirus vaccine, inactivated (DTaP-IPV), when administered to children 4 years through 6 years of age, for intramuscular use | GlaxoSmithKline | KINRIX™ | V06.3 | | 90698 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, haemophilus influenza Type B, and poliovirus vaccine, inactivated (DTaP-Hib-IPV), for intramuscular use | sanofi pasteur | Pentacel® | V06.3 plus V03.81 | | 90700 | Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to younger than seven years, for intramuscular use | sanofi pasteur sanofi pasteur GlaxoSmithKline | DAPTACEL® Tripedia® INFANRIX® | V06.1 | | 90702 | Diphtheria and tetanus toxoids (DT), adsorbed when administered to younger than seven years, for intramuscular use | sanofi pasteur | Diphtheria and Tetanus Toxoids Adsorbed | V06.5 | | 90707 | Measles, mumps, and rubella virus vaccine (MMR), live, for subcutaneous use | Merck | M-M-R II® | V06.4 | | 90710 | Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use | Merck | ProQuad® | V06.4 plus V05.4 | | 90713 | Poliovirus vaccine (IPV), inactivated, for subcutaneous or intramuscular use | sanofi pasteur | IPOL® | V04.0 | | 90714 | Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, when administered to seven years or older, for intramuscular use | sanofi pasteur | DECAVAC® | V06.5 | | 90715 | Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to 7 years or older, for intramuscular use | sanofi pasteur GlaxoSmithKline | ADACEL™ BOOSTRIX® | V06.1 | | 90716 | Varicella virus vaccine, live, for subcutaneous use | Merck | Varivax® | V05.4 | | 90718 | Tetanus and diphtheria toxoids (Td) adsorbed when administered to 7 years or older, for intramuscular use | sanofi pasteur | Tetanus and Diphtheria Toxoids Adsorbed for Adult Use | V06.5 | | 90721 | Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus influenza B vaccine (DTaP-Hib) | sanofi pasteur | TriHIBit® | V06.1 plus V03.81 | | 90723 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and poliovirus vaccine (DTaP-Hep B-IPV), for intramuscular use | GlaxoSmithKline | PEDIARIX® | V06.3 plus V03.81 | | Vaccine | | Manufacturer | Brand | ICD-9-CM | | 90732 | Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to 2 years or older, for subcutaneous or intramuscular use | Merck | PNEUMOVAX 23® | V03.82 | | 90733 | Meningococcal polysaccharide vaccine, for subcutaneous use | sanofi pasteur | Menomune® | V03.89 | | 90734 | Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetravalent), for intramuscular use | sanofi pasteur | Menactra® | V03.89 | | Novartis | Menveo® | | 90740 | Hepatitis B vaccine, dialysis or immunosuppressed patient dosage, 3 dose, for intramuscular use | Merck | RECOMBIVAX HB® | V05.3 | | 90743 | Hepatitis B vaccine, adolescent, 2 dose, for intramuscular use | Merck | RECOMBIVAX HB® | V05.3 | | 90744 | Hepatitis B, pediatric/adolescent dosage, 3 dose, for intramuscular use | Merck | RECOMBIVAX HB® | V05.3 | GlaxoSmithKline | Engerix-B® | | 90746 | Hepatitis B vaccine, adult dosage, for intramuscular use | Merck | RECOMBIVAX HB® | V05.3 | GlaxoSmithKline | ENERGIX-B® | | 90747 | Hepatitis B vaccine, dialysis or immunosuppressed patient dosage, 4 dose, for intramuscular use | GlaxoSmithKline | Engerix-B® | V05.3 | | 90748 | Hepatitis B and Hib (Hep B-Hib), for intramuscular use | Merck | COMVAX® | V06.8 | | 90749 | Unlisted vaccine or toxoid | Please | See | ICD-9-CM | | *Immunization Administration Codes | | ‡90470 | H1N1 immunization administration (intramuscular, intranasal), including counseling when performed | | | | Immunization Administration Under Age 8 With Physician Counseling | | 90465 | Immunization administration, first injection | | 90466 | Immunization administration, each additional injection | | 90467 | Immunization admin by intranasal/oral route, first administration | | 90468 | Immunization admin by intranasal/oral route, each additional administration | | | Immunization Administration | | 90471 | Immunization administration, one vaccine | | 90472 | Immunization administration, each additional vaccine | | 90473 | Immunization administration by intranasal/oral route; one vaccine | | 90474 | Immunization administration by intranasal/oral route; each additional vaccine |
|
Vaccine pending FDA approval [http://www.ama-assn.org/ama/pub/category/10902.html]
‡Effective 9/28/09, the AMA has released a new code specific to H1N1 immunization administration and revised existing code 90663 to include the H1N1 vaccine, which will streamline reporting and the reimbursement procedures for physicians and health care providers who are expected to administer nearly 200 million doses of the H1N1 vaccine in the United States. The codes will also help to efficiently report and track immunization and counseling services related to the H1N1 vaccine throughout the health care system. The codes are as follows: 90470 H1N1 immunization administration (intramuscular, intranasal), including counseling when performed 90663 Influenza virus vaccine, pandemic formulation, H1N1
To seek payment from payers following administration of 2009 H1N1 influenza type A monovalent vaccine, providers should bill CPT code 90663 (Influenza virus vaccine, pandemic formulation, H1N1) in conjunction with the immunization administration code 90470 (H1N1 immunization administration (intramuscular, intranasal), including counseling when performed). The 90663 code for the 2009 H1N1 vaccine itself should be billed for zero dollars, since the vaccine is provided free of charge by the federal government. Providers will be paid for 2009 H1N1 vaccine administration. To meet the needs of the Centers for Disease Control and Prevention (CDC) safety monitoring programs, the AMA suggests listing the National Drug Code (NDC) assigned by the US Food & Drug Administration (http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm) on the claim form (line 24) in addition to code 90663 (see National Uniform Claim Committee NUCC™ 1500 Claim Form Instruction Manual, pgs. 43-45 http://www.nucc.org/images/stories/PDF/claim_form_manual_v5-0_7-09.pdf). Developed and maintained by the American Academy of Pediatrics. For reporting purposes only. |
Can't find what you're looking for? Please contact us with your questions.
The recommendations in this publication do not indicate an exclusive course of treatment or serve as a standard of medical care.
Variations, taking into account individual circumstances, may be appropriate. This content is for informational purposes only. It is not intended to
constitute financial or legal advice. A financial advisor or attorney should be consulted if financial or legal advice is desired.
|